The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Single-institution experience of small cell bladder cancer at a community center.
 
Mina Makary
No Relationships to Disclose
 
Tullika Garg
Employment - DRPLZ (I)
Stock and Other Ownership Interests - DRPLZ (I)
 
Delnaz Bakht
No Relationships to Disclose
 
Zeeshan Solangi
No Relationships to Disclose
 
Karen Hassanzadeh
No Relationships to Disclose
 
Haiyan Liu
No Relationships to Disclose
 
Rajiv Prasanna Panikkar
No Relationships to Disclose
 
Joseph Vadakara
Research Funding - . Expanded Access Program for Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma who are Refractory to a Proteasome Inhibitor, and an Immunomodulatory Agent, and an Anti-CD38 Antibody (Inst); A Phase 2 Open-Label, Multi-Center, Randomized, Controlled, Dose-Finding Study of NLA101 in Adults Receiving High Dose Chemotherapy for Acute Myeloid Leukemia (Inst); A Phase 3, Randomized, Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL) (Inst); Connect MM (Inst); MHE112562 - Expanded Access To Mepolizumab For Patients With Hypereosinophilic Syndrome (Inst); PrE0905: Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML) (Inst); Prospective, Longitudinal, Non-Interventional Study Of Disease Burden And Treatment Of Patients With Low-Risk Myelofibrosis (MF) Or High-Risk Essential Thrombocythemia (ET) Or Et Patients Receiving Et-Directed Therapy (Inst)
 
Li Zhang
No Relationships to Disclose